









Markets
/
Stocks
/
nasdaq-dtil
/

Precision BioSciences Inc

DTIL

4.780USD

-0.130-2.65%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

55.62MMarket Cap

LossP/E TTM



Precision BioSciences Inc

4.780

-0.130-2.65%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company has shown average stock market performance, with mediocre fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

191 / 506

Overall Ranking

310 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

30.500

Target Price

+521.18%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision. ARCUS particularly generates defined outcomes due to predominant repair using homology directed repair (HDR) as opposed to non-homologous end joining (NHEJ). The Company’s in vivo gene editing programs include PBGENE-HBV, PBGENE-PMM, PBGENE-NVS, PBGENE-DMD, PBGENE-LL2, PBGENE-LL3 and iECURE-OTC. PBGENE-HBV program is designed for the potential treatment of chronic hepatitis B virus (HBV). The Company is pursuing development of PBGENE-PMM as a potential opportunity for treatment of m.3243 associated primary mitochondrial myopathy (PMM).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 173.71% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 68.70M.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 7.17M.%!(EXTRA int=2)

Fairly Valued

The company’s latest PE is -0.47, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.42M shares, decreasing 20.95% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 405.35K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.91.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 5.75, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 18.00K, representing a year-over-year decrease of 99.96%, while its net profit experienced a year-over-year decrease of 171.82%.

Score

Industry at a Glance

Previous score

5.75

Change



Financials

6.66

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.46

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.77

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.48, which is -1024.99% below the recent high of 4.47 and -227.51% above the recent low of -1.58.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 191/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Precision BioSciences Inc is 24.50, with a high of 60.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

30.500

Target Price

+538.08%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Precision BioSciences Inc

DTIL

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 4.57, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 5.23 and the support level at 4.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.57

Change

-0.17

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.066

Neutral

RSI(14)

48.699

Neutral

STOCH(KDJ)(9,3,3)

41.339

Buy

ATR(14)

0.268

Low Volatility

CCI(14)

-22.771

Neutral

Williams %R

58.209

Sell

TRIX(12,20)

-0.041

Sell

StochRSI(14)

75.407

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

4.678

Buy

MA10

4.807

Sell

MA20

4.914

Sell

MA50

4.797

Sell

MA100

4.841

Sell

MA200

4.958

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 48.90%, representing a quarter-over-quarter decrease of 11.78%. The largest institutional shareholder is The Vanguard, holding a total of 405.35K shares, representing 3.44% of shares outstanding, with 1.39% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Lynx1 Capital Advisors LLC

766.05K

Readout Capital LP

920.00K

Tang Capital Management, LLC

673.33K

Novartis Pharma AG

413.58K

The Vanguard Group, Inc.

Star Investors

281.08K

+1.03%

Benjamin (Weinstein)

395.49K

Acadian Asset Management LLC

248.62K

Smith (Matthew)

95.74K

Boothbay Fund Management, LLC

200.00K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.17, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.69. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.